WABCO Holdings Inc. (WBC) Analysts See $1.85 EPS; Biotime (BTX) Has 1.19 Sentiment

BioTime, Inc. (NYSEAMERICAN:BTX) Logo

Biotime Inc (BTX) investors sentiment decreased to 1.19 in Q4 2018. It’s down -0.20, from 1.39 in 2018Q3. The ratio dived, as 37 hedge funds increased and started new positions, while 31 reduced and sold stakes in Biotime Inc. The hedge funds in our database now own: 52.79 million shares, down from 55.13 million shares in 2018Q3. Also, the number of hedge funds holding Biotime Inc in top ten positions was flat from 2 to 2 for the same number . Sold All: 10 Reduced: 21 Increased: 22 New Position: 15.

Analysts expect WABCO Holdings Inc. (NYSE:WBC) to report $1.85 EPS on April, 18.They anticipate $0.12 EPS change or 6.09% from last quarter’s $1.97 EPS. WBC’s profit would be $95.05 million giving it 18.98 P/E if the $1.85 EPS is correct. After having $2.13 EPS previously, WABCO Holdings Inc.’s analysts see -13.15% EPS growth. The stock increased 0.31% or $0.44 during the last trading session, reaching $140.45. About 1.00 million shares traded or 88.18% up from the average. WABCO Holdings Inc. (NYSE:WBC) has risen 3.12% since March 17, 2018 and is uptrending. It has underperformed by 1.25% the S&P500. Some Historical WBC News: 18/04/2018 – Wabco Closes Above 50-Day Moving Average: Technicals; 12/04/2018 – Wabco Reaffirms Sees Sales Growth Outperforming Market Growth Long Term; 19/04/2018 – WABCO SEES YR EPS $6.95 TO $7.45, SAW $6.76 TO $7.26; 12/04/2018 – WABCO WINS $745M IN NEW IN PAST FOUR QUARTERS, COMPRISING $502M; 06/03/2018 WABCO Signs its Largest Ever Fleet Management Solutions Contract to Equip Girteka Logistics across Europe; 09/03/2018 – Wabco Holdings Names Fioroni Chief Financial Officer Effective June 6; 09/03/2018 – WABCO HOLDINGS INC SAYS HAS APPOINTED ROBERTO FIORONI TO ROLE OF CHIEF FINANCIAL OFFICER (CFO) STARTING BY JUNE 6, 2018; 11/04/2018 – Global Automotive Door Control Unit (DCU) Market Report 2017-2021 with Continental, Brose, WABCO and Sioux Logena Dominating – ResearchAndMarkets.com; 28/05/2018 – BSE Mumbai Bourse: Results from WABCO-TVS (India) for Apr 01 to Mar 31; 19/04/2018 – WABCO HOLDINGS INC – SEES PERFORMANCE FULL YEAR 2018 DILUTED EPS TO NOW RANGE FROM $7.30 TO $7.80

The stock increased 11.61% or $0.18 during the last trading session, reaching $1.73. About 2.53M shares traded or 137.99% up from the average. BioTime, Inc. (BTX) has declined 42.59% since March 17, 2018 and is downtrending. It has underperformed by 46.96% the S&P500. Some Historical BTX News: 17/05/2018 – AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine; 24/05/2018 – BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites; 15/03/2018 – BioTime 4Q Loss $72.1M; 16/04/2018 – Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018; 13/03/2018 – BioTime Submits CE Mark Application for European Approval of Renevia(R); 27/03/2018 – BIOTIME – UPON TERMINATION OF ESCROW, AGEX WILL RECEIVE REMAINDER OF CONSIDERATION SUBJECT TO DEDUCTIONS OF LIABILITIES AND/OR EXPENSES FROM ESCROW; 15/03/2018 – BioTime Closes Below 200-Day Moving Average: Technicals; 27/03/2018 – BioTime: IVT Holdings Acquired Ascendance Biotechnology Inc; 27/03/2018 – BioTime Announces Cash Sale of Ascendance Biotechnology; 24/05/2018 – BioTime at Non-Deal Roadshow Hosted By Chardan Today

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $265.69 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It currently has negative earnings. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

Analysts await BioTime, Inc. (NYSEAMERICAN:BTX) to report earnings on March, 21. They expect $-0.07 EPS, up 12.50% or $0.01 from last year’s $-0.08 per share. After $-0.07 actual EPS reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

More notable recent BioTime, Inc. (NYSEAMERICAN:BTX) news were published by: Businesswire.com which released: “BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company – Business Wire” on March 11, 2019, also Businesswire.com with their article: “BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update – Business Wire” published on March 14, 2019, Prnewswire.com published: “Uranium Energy Corp Files Fiscal 2019 Q2 Report – PRNewswire” on March 12, 2019. More interesting news about BioTime, Inc. (NYSEAMERICAN:BTX) were released by: Prnewswire.com and their article: “Uranium Energy Corp Receives Radioactive Material License for the Burke Hollow ISR Project in South Texas – PRNewswire” published on February 20, 2019 as well as Businesswire.com‘s news article titled: “AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American – Business Wire” with publication date: November 29, 2018.

Broadwood Capital Inc holds 3.84% of its portfolio in BioTime, Inc. for 29.97 million shares. Prescott General Partners Llc owns 1.85 million shares or 0.07% of their US portfolio. Moreover, Dafna Capital Management Llc has 0.05% invested in the company for 100,000 shares. The California-based Destination Wealth Management has invested 0.03% in the stock. Indexiq Advisors Llc, a New York-based fund reported 781,328 shares.

WABCO Holdings Inc., together with its subsidiaries, provides electronic, mechanical, electro-mechanical, and aerodynamic products for commercial truck, bus, trailer, and passenger car manufacturers worldwide. The company has market cap of $7.22 billion. It engineers, develops, makes, and sells control systems, including braking, stability, suspension, transmission automation, and air management systems primarily for commercial vehicles. It has a 18.9 P/E ratio. The firm offers pneumatic anti-lock braking systems, electronic braking systems, electronic stability control systems, brake controls, automated manual transmission systems, and air disc brakes; and various conventional mechanical products, such as actuators, air compressors, conventional braking systems, and air control valves for medium and heavy-duty trucks, buses, and trailers, as well as foundation brakes, vehicle electronic stability control and roll stability support systems, and advanced driver assistance systems.

Among 8 analysts covering WABCO Holdings (NYSE:WBC), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. WABCO Holdings had 24 analyst reports since September 24, 2018 according to SRatingsIntel. The firm has “Buy” rating by Citigroup given on Thursday, February 28. JP Morgan downgraded it to “Underweight” rating and $98 target in Thursday, January 10 report. The stock of WABCO Holdings Inc. (NYSE:WBC) earned “Hold” rating by Mizuho on Tuesday, February 26. Citigroup maintained the stock with “Buy” rating in Friday, October 19 report. The stock of WABCO Holdings Inc. (NYSE:WBC) has “Outperform” rating given on Thursday, February 7 by Robert W. Baird. As per Friday, October 19, the company rating was maintained by Robert W. Baird. The firm has “Buy” rating given on Friday, March 15 by Citigroup. On Tuesday, February 19 the stock rating was maintained by Morgan Stanley with “Hold”. Morgan Stanley maintained it with “Equal-Weight” rating and $137 target in Monday, March 4 report. KeyBanc Capital Markets maintained WABCO Holdings Inc. (NYSE:WBC) rating on Thursday, February 28. KeyBanc Capital Markets has “Buy” rating and $150 target.

Investors sentiment decreased to 0.88 in Q4 2018. Its down 0.05, from 0.93 in 2018Q3. It fall, as 36 investors sold WABCO Holdings Inc. shares while 95 reduced holdings. 31 funds opened positions while 84 raised stakes. 50.46 million shares or 1.46% more from 49.73 million shares in 2018Q3 were reported. Amalgamated Retail Bank owns 0.04% invested in WABCO Holdings Inc. (NYSE:WBC) for 11,766 shares. Great West Life Assurance Can invested in 0% or 14,692 shares. Sterling Global Strategies Limited Company stated it has 0% of its portfolio in WABCO Holdings Inc. (NYSE:WBC). Mitsubishi Ufj Tru Bk Corporation, Japan-based fund reported 47,340 shares. Captrust Fin Advisors invested in 0% or 167 shares. Nordea Inv Mgmt Ab accumulated 1,695 shares. 46,905 were reported by Employees Retirement Sys Of Ohio. Penn Capital Com Inc holds 3,381 shares. Scotia Cap holds 0.01% or 8,185 shares. Fjarde Ap reported 0.04% stake. Dupont Mgmt holds 0.04% or 15,505 shares. Financial Bank Of America De holds 0.01% of its portfolio in WABCO Holdings Inc. (NYSE:WBC) for 366,457 shares. Moreover, Northwestern Mutual Wealth Management has 0% invested in WABCO Holdings Inc. (NYSE:WBC). 8,069 are owned by Dekabank Deutsche Girozentrale. Eaton Vance Mgmt owns 4,375 shares.

WABCO Holdings Inc. (NYSE:WBC) Institutional Positions Chart